AUG 1 9 2005

ITW

Docket No. MCP-5019

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Marni L. Allen, et al.

Serial No.: 10/743,126

Art Unit: 1642

Filed

: December 22, 2003

Examiner: Thurman Page

For

: CONSUMER CUSTOMIZED DOSAGE FORMS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

August 12, 2005
(Date of Deposit)

Michele G. Mangini
(Name of applicant, assignee, or Registered Representative)

August 12,2005

(Date of Signature)

Commissioner for Patents P.O. Box 1450 Washington, D.C. 20231

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement mailed on December 22, 2003.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this

information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information

 \boxtimes

Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with [] the first or second After Final Submission, therefore: Statement in Accordance with §1.97(e) (attached); or П Please charge Deposit Account No. 10-/ the fee of \$180.00 as set forth in §1.17(p). In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

☐ Statement in	Accordance with §1.97(e)
(attached);	or
Please charg	e Deposit Account No. 10-
0750/ /	the fee of \$180.00 as set forth
in §1.17(p).
☐ In accordance wit	h §1.97(d), this Information
Disclosure Statement is being	ng filed after the mailing date of
either a Final Action under	§1.113 or a Notice of Allowance
under §1.311 but before the	e payment of the Issue Fee.
Applicant(s) hereby petition	n(s) for consideration of this
Information Disclosure State	ement. Included are: Statement in
Accordance with §1.97(e) as	set forth below and the fee of
\$180.00 as set forth in §1.3	17(p).
— -	the references listed on the
attached Form PTO-1449 are	enclosed herewith.
☐ Copies of referen	ces listed on the attached Form PTO
1449 are enclosed herewith	EXCEPT THAT:
☐ In view of t	he voluminous nature of references
[list as app	ropriate], and the likelihood that
these refere	nces are available to the Examiner,
copies are n	ot enclosed herewith.
☐ If any of th	e foregoing publications are not
_	the Examiner, Applicant will
	supply copies at the Examiner's
request.	
	reign patent documents and non-
patent literature are enclos	sed in accordance with 37 CFR 1.98

(a)(2).

igtiim There are no listed references which are not in the English language.

The relevance of those listed references which are not in the English language is as follows:

Attached are copies of search report(s) from corresponding patent application(s) PCT/US 2004/042398 (Attorney docket number MCP5019PCT) and PCT/US 2004/042150 (Attorney docket number MCP5022PCT), which are listed on the attached Submission Under MPEP 609 D. Applicants further wish to point out related application, U.S.S.N. 10/743,127 filed 22 December 2003, (MCP 5022) having U.S. Patent Publication No. 2005-0136119A1, which is also listed on the Submission Under MPEP 609D.

Copies of the references listed on the search report(s) are included except for those previously cited in an IDS mailed December 22, 2003.

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/MCP5019/MGM. This form is submitted in triplicate.

Respectfully submitted,

Michelle G. Mangini

Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-2810 DATED: August 12, 2005



SUBMISSION UNDER MPEP 609 D

Page 1 of 1

Application Number	10/743,126
Filing Date	December 22, 2003
First Named Inventor	Marni Allen
Group Art Unit	1642
Examiner Name	Thurman Page
Attorney Docket Number	MCP-5019

		U.S. PATE	ENT DOCUMENTS			
			U.S. Patent Document		Pages, Columns, Lines,	
Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	Number	Kind Code ² (if known)	where relevant passages or relevant figures appear	
		Bunick, et al.	US2005-0136119	A1		
4		1	1		1	

FOREIGN PATENT DOCUMENTS

		· I OKLIO	TIAIENT	DOCUME	110		
Examiner Initials	Cite No.1	Name of Patentee or Applicant of Cited Document	Foreign P	atent Docum	ent KindCode ⁵	Pages, Columns, Lines, where relevant passages or relevant figures appear	Т ⁸
							-
						,	
		OTHER PRIOR ART - N	ON PATENT	LITERATU	RE DOCUMEN	ITS	
Examiner 's Initials*	Cite No.1	Include name of the author (in C title of the item (book, magazine volume-issue number(s	, journal, s	erial, symp	osium, catalo	g, etc.), date, page(s),	T²
		PCT Search Report PCT/UNo. MCP5019PCT)	JS2004/	042398	dated June	e 8, 2005 (Atty Dkt	
		PCT Search Report PCT/U No. MCP5022PCT)	S2004/0	42150 d	ated May :	30, 2005 (Attny Dkt	
L							

Examiner	D	Date	
Signature		Considered	·



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

o a collection of information unless it displays	a valid OMB control number
Application Number	10/743,126
Filing Date	
First Named Inventor	December 22, 2003
Group Art Unit	Marni Allen
Group Art Unit	1642
Examiner Name	Thurman Page
Attorney Docket Number	MCP-5019
	1

	T	LIC Dotters D		U.S. PATENT DOCUMENTS		
Examiner		U.S. Patent Docu				
Initials	Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages relevant figures appear
		5,620,707	Α	Sanker et al.	04-15-1997	and agreed appear
		6,482,433	B1	DeRoss et al.	11-19-2002	
			-++			
			+-+			
	$\neg \uparrow$					
	=== <u>L</u> .		FOREIC	GN PATENT DOCUMENTS		- · · · ·

]	Foreign	Patent Docume	- FUR	EIGN PATENT DOCUMENTS			
Examiner Initials	Cite No.1	Office ³		ndCode ⁵	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		EP	0298740	Α	American Home Products Corp	01-11-1989		-
		EP	0570327	Α	Fuisz Technologies Ltd	11-18-1993		<u> </u>
		GB	2147501	Α	Avner * Rotman	05-15-1985		
								·
		L	<u>_</u>					

Examiner			
Signature	Date	T	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with and not considered. Include copy of this form with a second citation is in conformance with a second citation.	Considered		
and not considered. Include copy of this form with	MPEP 609 Dra	W line through six-	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark 1450 Alexandria VA 22313-1450

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial possible. 6 Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

Application Number	10/743,126
Filing Date	December 22, 2003
First Named Inventor	Marni Allen
Group Art Unit	1642
Examiner Name	Thurman Page
Attorney Docket Number	MCP-5019

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	-	CHAWLA J ET AL: "Effect of Route of Administration on the Pharmacokinetic Behavior of Enantiomers of Nefopam and Desmethylnefopam" Therapeutic Drug Monitoring, New York, NY, US Vol. 25, No. 2, April 2003 pages 203-210, XP008046826 ISSN: 0163-4356 page 204, right hand column, lines 44, 45	
	•	DATABASE WPI Section Ch, Week 200378 Derwent Publications Ltd., London, GB; Class A96, AN 2002-845036 XP002327004 & WO 03/074086 A1 (Medrx Co Ltf) 12 September 2003 abstract	

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.